US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Lexeo Therapeutics

5.46

-0.1900-3.36%

Post-market: 5.460.00000.00%16:39 EDT

Volume:881.59K

Turnover:4.88M

Market Cap:398.51M

PE:-2.18

High:5.78

Open:5.59

Low:5.43

Close:5.65

52wk High:10.99

52wk Low:1.45

Shares:72.99M

Float Shares:45.01M

Volume Ratio:0.88

T/O Rate:1.96%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.5000

EPS(LYR):-3.0934

ROE:-80.69%

ROA:-44.66%

PB:3.30

PE(LYR):-1.77

Loading ...

Overview Company News Filings

Institutional investors have a lot riding on Lexeo Therapeutics, Inc. (NASDAQ:LXEO) with 56% ownership

Simply Wall St.

Lexeo Therapeutics Partners with Johnson & Johnson on Targeted Cardiac Gene Therapy

Lexeo Therapeutics Inc - Announces Research Collaboration With Johnson & Johnson

THOMSON REUTERS

Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of Aav Gene Therapy

THOMSON REUTERS

Lexeo Therapeutics CEO to Present at J.P. Morgan Healthcare Conference

Raymond James Initiates Coverage on Lexeo Therapeutics With Strong Buy Rating, $25 Price Target

MT Newswires Live

Lexeo Therapeutics Initiated at Strong Buy by Raymond James

Lexeo Therapeutics Is Maintained at Buy by Chardan Capital

Lexeo Therapeutics Hosts Virtual Clinician Event on PKP2-Associated Arrhythmogenic Cardiomyopathy

Lexeo Therapeutics Initiated at Overweight by Cantor Fitzgerald

Lexeo Therapeutics Initiated at Overweight by Cantor Fitzgerald

Lexeo Therapeutics initiated with an Overweight at Cantor Fitzgerald

Optimistic Buy Rating for Lexeo Therapeutics Driven by High-Dose Potential and Superior Safety Profile

Lexeo Therapeutics Reports Decreased Losses and Strong Cash Position

Lexeo Therapeutics unveils gene therapy advances targeting cardiac diseases with no existing treatments

Lexeo Therapeutics Is Maintained at Buy by Chardan Capital

Lexeo Therapeutics Q3 EPS $(0.33) Beats $(0.54) Estimate

Lexeo Therapeutics reports interim LX2006 trial data showing improvements in cardiac and neurologic measures

Lexeo Therapeutics Inc - EPS $-0.33 for Q3

THOMSON REUTERS

Press Release: Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LXEO/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"LXEO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LXEO\",,,,,undefined,":{"symbol":"LXEO","market":"US","secType":"STK","nameCN":"Lexeo Therapeutics","latestPrice":5.46,"timestamp":1774641600000,"preClose":5.65,"halted":0,"volume":881585,"hourTrading":{"tag":"盘后","latestPrice":5.46,"preClose":5.46,"latestTime":"16:39 EDT","volume":11926,"amount":65116.01,"timestamp":1774643957744,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.033628318584070865,"floatShares":45005000,"shares":72987327,"eps":-2.5,"marketStatus":"Market Closed","change":-0.19,"latestTime":"03-27 16:00:00 EDT","open":5.59,"high":5.7799,"low":5.431,"amount":4882878.6542745,"amplitude":0.061752,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.5,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"listingDate":1698984000000,"exchange":"NASDAQ","adjPreClose":5.65,"preHourTrading":{"tag":"盘前","latestPrice":5.55,"preClose":5.65,"latestTime":"09:29 EDT","volume":219,"amount":1224.2400030000001,"timestamp":1774618199999,"change":-0.1,"changeRate":-0.017699,"amplitude":0.00177},"postHourTrading":{"tag":"盘后","latestPrice":5.46,"preClose":5.46,"latestTime":"16:39 EDT","volume":11926,"amount":65116.01,"timestamp":1774643957744,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8827238284221851,"impliedVol":1.3093,"impliedVolPercentile":0.6614},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LXEO\",,,,,undefined,":{"symbol":"LXEO","floatShares":45005000,"roa":"-44.66%","roe":"-80.69%","lyrEps":-3.093449,"volumeRatio":0.8827238284221851,"shares":72987327,"dividePrice":0,"high":5.7799,"amplitude":0.061752,"preClose":5.65,"low":5.431,"week52Low":1.45,"pbRate":"3.30","week52High":10.99,"institutionHeld":0,"latestPrice":5.46,"eps":-2.5,"divideRate":0,"volume":881585,"delay":0,"ttmEps":-2.5,"open":5.59,"prevYearClose":9.93,"prevWeekClose":5.65,"prevMonthClose":7.18,"prevQuarterClose":9.93,"fiveDayClose":5.65,"twentyDayClose":7.18,"sixtyDayClose":9.74},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LXEO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-05","symbol":"LXEO","fiscalQuarterEnding":"2025/09","expectedEps":-0.48,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"pre","actualEps":-0.33},{"market":"US","date":"2025-08-14","symbol":"LXEO","fiscalQuarterEnding":"2025/06","expectedEps":-0.64,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"pre","actualEps":-0.6},{"market":"US","date":"2025-05-12","symbol":"LXEO","fiscalQuarterEnding":"2025/03","expectedEps":-0.8,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"pre","actualEps":-0.99}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LXEO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LXEO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5455,"buy":0.4545,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5455,"analysts":11,"updateTime":1766030400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LXEO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LXEO","date":"2026-03-27","current":-2.184,"percent":0.554404,"low":-8.903248,"twenty":-6.202926,"median":-4.267198,"eighty":-2.118489,"high":-0.6043,"avg":-4.150267,"sd":2.059335,"marketCap":412378397},"quantilePoints":[{"date":"2023-11-03","current":-4.257819,"twenty":-4.257819,"median":-4.257819,"eighty":-4.257819,"marketCap":271355051},{"date":"2023-11-10","current":-4.199758,"twenty":-4.199758,"median":-4.091377,"eighty":-4.048799,"marketCap":267654754},{"date":"2023-11-17","current":-4.292656,"twenty":-4.257819,"median":-4.118472,"eighty":-4.064282,"marketCap":273575228},{"date":"2023-11-24","current":-4.373941,"twenty":-4.270979,"median":-4.199758,"eighty":-4.070475,"marketCap":278755643},{"date":"2023-12-01","current":-4.923587,"twenty":-4.377038,"median":-4.259754,"eighty":-4.081313,"marketCap":313785113},{"date":"2023-12-08","current":-5.031968,"twenty":-4.945263,"median":-4.26556,"eighty":-4.111505,"marketCap":320692333},{"date":"2023-12-15","current":-4.58828,"twenty":-4.855461,"median":-4.333298,"eighty":-4.161824,"marketCap":306423687},{"date":"2023-12-22","current":-5.849059,"twenty":-5.408075,"median":-4.389424,"eighty":-4.194339,"marketCap":390623587},{"date":"2023-12-29","current":-5.805172,"twenty":-5.505138,"median":-4.537237,"eighty":-4.207282,"marketCap":387692577},{"date":"2024-01-05","current":-5.857039,"twenty":-5.805172,"median":-4.621669,"eighty":-4.218567,"marketCap":391156497},{"date":"2024-01-12","current":-5.896937,"twenty":-5.857039,"median":-4.799136,"eighty":-4.257819,"marketCap":393821051},{"date":"2024-01-19","current":-6.012642,"twenty":-5.955803,"median":-4.957419,"eighty":-4.257819,"marketCap":401548257},{"date":"2024-01-26","current":-6.66298,"twenty":-6.148663,"median":-5.403559,"eighty":-4.260916,"marketCap":444980484},{"date":"2024-02-02","current":-6.706868,"twenty":-6.322251,"median":-5.468033,"eighty":-4.26169,"marketCap":447911493},{"date":"2024-02-09","current":-6.714848,"twenty":-6.590366,"median":-5.777243,"eighty":-4.264786,"marketCap":448444404},{"date":"2024-02-16","current":-6.072489,"twenty":-6.589568,"median":-5.827115,"eighty":-4.287237,"marketCap":405545088},{"date":"2024-02-23","current":-6.343796,"twenty":-6.544084,"median":-5.876988,"eighty":-4.341427,"marketCap":423664054},{"date":"2024-03-01","current":-5.8331,"twenty":-6.543286,"median":-5.916886,"eighty":-4.373941,"marketCap":389557765},{"date":"2024-03-08","current":-5.857039,"twenty":-6.520145,"median":-5.890953,"eighty":-4.383231,"marketCap":391156497},{"date":"2024-03-15","current":-6.292966,"twenty":-6.520145,"median":-5.916886,"eighty":-4.447485,"marketCap":417815207},{"date":"2024-03-22","current":-6.028084,"twenty":-6.505782,"median":-5.977118,"eighty":-4.547445,"marketCap":400228597},{"date":"2024-03-28","current":-6.128418,"twenty":-6.497802,"median":-5.937219,"eighty":-4.601636,"marketCap":406890192},{"date":"2024-04-05","current":-5.265543,"twenty":-6.474661,"median":-5.932845,"eighty":-4.625869,"marketCap":349600479},{"date":"2024-04-12","current":-5.241463,"twenty":-6.410602,"median":-5.90231,"eighty":-4.683238,"marketCap":348001696},{"date":"2024-04-19","current":-4.844139,"twenty":-6.359022,"median":-5.876988,"eighty":-4.791277,"marketCap":321621782},{"date":"2024-04-26","current":-4.88026,"twenty":-6.350977,"median":-5.858281,"eighty":-4.83704,"marketCap":324019956},{"date":"2024-05-03","current":-6.182772,"twenty":-6.32828,"median":-5.876988,"eighty":-4.840714,"marketCap":410498948},{"date":"2024-05-10","current":-6.881509,"twenty":-6.410602,"median":-5.90231,"eighty":-4.84735,"marketCap":477707444},{"date":"2024-05-17","current":-6.653707,"twenty":-6.497802,"median":-5.932845,"eighty":-4.860193,"marketCap":461893680},{"date":"2024-05-24","current":-7.346604,"twenty":-6.546981,"median":-6.018356,"eighty":-4.875444,"marketCap":509993878},{"date":"2024-05-31","current":-7.617118,"twenty":-6.584345,"median":-6.028342,"eighty":-4.885879,"marketCap":528772723},{"date":"2024-06-07","current":-8.28154,"twenty":-6.629029,"median":-6.03658,"eighty":-4.908353,"marketCap":574896200},{"date":"2024-06-14","current":-8.903248,"twenty":-6.66298,"median":-6.072489,"eighty":-4.908353,"marketCap":618054597},{"date":"2024-06-21","current":-7.441521,"twenty":-6.711656,"median":-6.103378,"eighty":-4.917985,"marketCap":516582946},{"date":"2024-06-28","current":-7.05236,"twenty":-6.714848,"median":-6.103378,"eighty":-4.921032,"marketCap":489567767},{"date":"2024-07-05","current":-7.066597,"twenty":-6.782675,"median":-6.120366,"eighty":-4.923587,"marketCap":490556127},{"date":"2024-07-12","current":-8.276794,"twenty":-6.842522,"median":-6.15029,"eighty":-4.991251,"marketCap":574566747},{"date":"2024-07-15","current":-8.352728,"twenty":-6.873712,"median":-6.156275,"eighty":-4.995541,"marketCap":579838001},{"date":"2024-08-02","current":-6.198104,"twenty":-6.865914,"median":-6.161186,"eighty":-4.999831,"marketCap":430266153},{"date":"2024-08-09","current":-5.54792,"twenty":-6.840926,"median":-6.144305,"eighty":-5.014306,"marketCap":385131036},{"date":"2024-08-16","current":-5.180835,"twenty":-6.826318,"median":-6.112265,"eighty":-5.010821,"marketCap":400038148},{"date":"2024-08-23","current":-5.215088,"twenty":-6.797868,"median":-6.103378,"eighty":-5.014306,"marketCap":402683028},{"date":"2024-08-30","current":-4.975314,"twenty":-6.782675,"median":-6.066504,"eighty":-4.996865,"marketCap":384168866},{"date":"2024-09-06","current":-4.881117,"twenty":-6.774695,"median":-6.03259,"eighty":-4.924513,"marketCap":376895445},{"date":"2024-09-13","current":-4.22602,"twenty":-6.738787,"median":-6.028084,"eighty":-4.89684,"marketCap":326312109},{"date":"2024-09-20","current":-4.461512,"twenty":-6.721232,"median":-5.996218,"eighty":-4.873838,"marketCap":344495661},{"date":"2024-09-27","current":-3.814978,"twenty":-6.714848,"median":-5.932845,"eighty":-4.83926,"marketCap":294573545},{"date":"2024-10-04","current":-3.900612,"twenty":-6.71405,"median":-5.90231,"eighty":-4.736975,"marketCap":301185746},{"date":"2024-10-11","current":-3.408218,"twenty":-6.71006,"median":-5.876988,"eighty":-4.623769,"marketCap":263165591},{"date":"2024-10-18","current":-3.89633,"twenty":-6.698313,"median":-5.858281,"eighty":-4.466448,"marketCap":300855136},{"date":"2024-10-25","current":-4.238865,"twenty":-6.663872,"median":-5.849059,"eighty":-4.397847,"marketCap":327303939},{"date":"2024-10-31","current":-3.543091,"twenty":-6.66298,"median":-5.819389,"eighty":-4.373941,"marketCap":273579808},{"date":"2024-11-08","current":-3.378247,"twenty":-6.65417,"median":-5.783228,"eighty":-4.26556,"marketCap":260851321},{"date":"2024-11-15","current":-2.970727,"twenty":-6.653707,"median":-5.678921,"eighty":-4.257819,"marketCap":257253067},{"date":"2024-11-22","current":-2.367417,"twenty":-6.629978,"median":-5.544882,"eighty":-4.208893,"marketCap":205008871},{"date":"2024-11-29","current":-3.142556,"twenty":-6.626181,"median":-5.512207,"eighty":-4.166207,"marketCap":272132743},{"date":"2024-12-06","current":-2.703438,"twenty":-6.607553,"median":-5.450079,"eighty":-4.100138,"marketCap":234106904},{"date":"2024-12-13","current":-2.72253,"twenty":-6.599941,"median":-5.414849,"eighty":-4.066934,"marketCap":235760202},{"date":"2024-12-20","current":-2.306323,"twenty":-6.589568,"median":-5.281597,"eighty":-3.914314,"marketCap":199718319},{"date":"2024-12-27","current":-2.588885,"twenty":-6.578686,"median":-5.241463,"eighty":-3.893837,"marketCap":224187120},{"date":"2025-01-03","current":-2.546883,"twenty":-6.570706,"median":-5.215088,"eighty":-3.826967,"marketCap":220549866},{"date":"2025-01-10","current":-2.604159,"twenty":-6.564766,"median":-5.210806,"eighty":-3.754178,"marketCap":225509758},{"date":"2025-01-17","current":-1.981757,"twenty":-6.550955,"median":-5.17013,"eighty":-3.659982,"marketCap":171612264},{"date":"2025-01-24","current":-2.142882,"twenty":-6.53506,"median":-5.110187,"eighty":-3.528106,"marketCap":185565027},{"date":"2025-01-31","current":-2.005371,"twenty":-6.527327,"median":-5.031968,"eighty":-3.425345,"marketCap":173657111},{"date":"2025-02-07","current":-2.070307,"twenty":-6.515357,"median":-5.011134,"eighty":-3.395373,"marketCap":179280293},{"date":"2025-02-14","current":-1.611936,"twenty":-6.499398,"median":-4.991251,"eighty":-3.192195,"marketCap":139587239},{"date":"2025-02-21","current":-1.539361,"twenty":-6.496206,"median":-4.928215,"eighty":-3.10819,"marketCap":133302506},{"date":"2025-02-28","current":-1.142107,"twenty":-6.453914,"median":-4.914373,"eighty":-2.892068,"marketCap":98901859},{"date":"2025-03-07","current":-1.073351,"twenty":-6.437026,"median":-4.893962,"eighty":-2.779043,"marketCap":92947901},{"date":"2025-03-14","current":-1.134467,"twenty":-6.376035,"median":-4.880688,"eighty":-2.703438,"marketCap":98240308},{"date":"2025-03-21","current":-1.027514,"twenty":-6.356851,"median":-4.852166,"eighty":-2.601104,"marketCap":88978596},{"date":"2025-03-28","current":-1.387527,"twenty":-6.34619,"median":-4.840506,"eighty":-2.545356,"marketCap":136439657},{"date":"2025-04-04","current":-0.891258,"twenty":-6.338037,"median":-4.795483,"eighty":-2.464405,"marketCap":87640072},{"date":"2025-04-11","current":-0.732587,"twenty":-6.311324,"median":-4.74555,"eighty":-2.42393,"marketCap":72037483},{"date":"2025-04-17","current":-0.769723,"twenty":-6.30019,"median":-4.649906,"eighty":-2.355198,"marketCap":75689153},{"date":"2025-04-25","current":-1.238984,"twenty":-6.294572,"median":-4.621669,"eighty":-2.271508,"marketCap":121832978},{"date":"2025-05-02","current":-1.590085,"twenty":-6.292966,"median":-4.546304,"eighty":-2.190247,"marketCap":156357855},{"date":"2025-05-09","current":-1.012793,"twenty":-6.292343,"median":-4.461512,"eighty":-2.110502,"marketCap":99590991},{"date":"2025-05-16","current":-0.81978,"twenty":-6.289736,"median":-4.386933,"eighty":-1.999259,"marketCap":89607702},{"date":"2025-05-23","current":-0.935157,"twenty":-6.278497,"median":-4.373941,"eighty":-1.883139,"marketCap":102219157},{"date":"2025-05-30","current":-0.871396,"twenty":-6.262715,"median":-4.292656,"eighty":-1.737224,"marketCap":95249669},{"date":"2025-06-06","current":-0.992845,"twenty":-6.24372,"median":-4.263625,"eighty":-1.61652,"marketCap":108524884},{"date":"2025-06-13","current":-2.052375,"twenty":-6.232879,"median":-4.257819,"eighty":-1.598825,"marketCap":224338921},{"date":"2025-06-20","current":-2.127645,"twenty":-6.223303,"median":-4.238865,"eighty":-1.614228,"marketCap":232566510},{"date":"2025-06-27","current":-2.06491,"twenty":-6.203846,"median":-4.21373,"eighty":-1.629508,"marketCap":225709077},{"date":"2025-07-03","current":-2.198289,"twenty":-6.20262,"median":-4.195762,"eighty":-1.653954,"marketCap":240288372},{"date":"2025-07-11","current":-2.267449,"twenty":-6.200163,"median":-4.140386,"eighty":-1.70361,"marketCap":247848006},{"date":"2025-07-18","current":-2.104429,"twenty":-6.198104,"median":-4.103992,"eighty":-1.718889,"marketCap":230028868},{"date":"2025-07-25","current":-1.812971,"twenty":-6.182772,"median":-4.083635,"eighty":-1.764727,"marketCap":198170410},{"date":"2025-08-01","current":-2.336608,"twenty":-6.17781,"median":-4.06594,"eighty":-1.812971,"marketCap":255407640},{"date":"2025-08-08","current":-2.198289,"twenty":-6.166096,"median":-4.041907,"eighty":-1.86404,"marketCap":240288372},{"date":"2025-08-15","current":-2.26542,"twenty":-6.156275,"median":-3.900612,"eighty":-1.87168,"marketCap":258647483},{"date":"2025-08-22","current":-2.26069,"twenty":-6.144305,"median":-3.890098,"eighty":-1.890778,"marketCap":258107509},{"date":"2025-08-29","current":-2.251231,"twenty":-6.128418,"median":-3.827824,"eighty":-1.92165,"marketCap":257027562},{"date":"2025-09-05","current":-2.35055,"twenty":-6.121976,"median":-3.799992,"eighty":-1.925602,"marketCap":268367013},{"date":"2025-09-12","current":-2.449869,"twenty":-6.107404,"median":-3.74219,"eighty":-1.93461,"marketCap":279706464},{"date":"2025-09-19","current":-2.582295,"twenty":-6.103535,"median":-3.677964,"eighty":-1.952307,"marketCap":294825733},{"date":"2025-09-26","current":-3.07416,"twenty":-6.103378,"median":-3.543091,"eighty":-1.960886,"marketCap":350983015},{"date":"2025-10-03","current":-3.16875,"twenty":-6.084882,"median":-3.508838,"eighty":-1.966064,"marketCap":361782492},{"date":"2025-10-10","current":-3.878171,"twenty":-6.074043,"median":-3.510979,"eighty":-1.967068,"marketCap":442778573},{"date":"2025-10-17","current":-4.147751,"twenty":-6.062913,"median":-3.59126,"eighty":-1.975097,"marketCap":473557083},{"date":"2025-10-24","current":-4.256529,"twenty":-6.041368,"median":-3.707936,"eighty":-1.980826,"marketCap":485976483},{"date":"2025-10-31","current":-5.750439,"twenty":-6.046619,"median":-3.744331,"eighty":-1.985047,"marketCap":656539109},{"date":"2025-11-07","current":-5.854784,"twenty":-6.046619,"median":-3.79777,"eighty":-1.986886,"marketCap":614553293},{"date":"2025-11-14","current":-6.25113,"twenty":-6.074043,"median":-3.827824,"eighty":-1.989502,"marketCap":656156069},{"date":"2025-11-21","current":-6.195502,"twenty":-6.104132,"median":-3.878171,"eighty":-2.002315,"marketCap":650317083},{"date":"2025-11-28","current":-6.856078,"twenty":-6.134773,"median":-3.890098,"eighty":-2.017382,"marketCap":719655044},{"date":"2025-12-05","current":-6.320664,"twenty":-6.150597,"median":-3.89885,"eighty":-2.031318,"marketCap":663454802},{"date":"2025-12-12","current":-6.814357,"twenty":-6.187864,"median":-3.917739,"eighty":-2.03527,"marketCap":715275804},{"date":"2025-12-19","current":-6.925612,"twenty":-6.202522,"median":-4.030982,"eighty":-2.038234,"marketCap":726953776},{"date":"2025-12-26","current":-7.342817,"twenty":-6.232879,"median":-4.056541,"eighty":-2.044162,"marketCap":770746173},{"date":"2026-01-02","current":-6.904752,"twenty":-6.267809,"median":-4.06981,"eighty":-2.050547,"marketCap":724764157},{"date":"2026-01-09","current":-6.584894,"twenty":-6.292758,"median":-4.093288,"eighty":-2.054882,"marketCap":691189986},{"date":"2026-01-16","current":-5.215069,"twenty":-6.292758,"median":-4.112303,"eighty":-2.065989,"marketCap":547404952},{"date":"2026-01-23","current":-5.340231,"twenty":-6.291928,"median":-4.144069,"eighty":-2.070307,"marketCap":560542671},{"date":"2026-01-30","current":-5.263743,"twenty":-6.288275,"median":-4.176128,"eighty":-2.074127,"marketCap":552514065},{"date":"2026-02-06","current":-4.79091,"twenty":-6.285897,"median":-4.204325,"eighty":-2.07973,"marketCap":502882683},{"date":"2026-02-13","current":-4.568401,"twenty":-6.271979,"median":-4.22602,"eighty":-2.08467,"marketCap":479526738},{"date":"2026-02-20","current":-4.359798,"twenty":-6.2553,"median":-4.256529,"eighty":-2.093982,"marketCap":457630540},{"date":"2026-02-27","current":-4.797864,"twenty":-6.249281,"median":-4.259754,"eighty":-2.101306,"marketCap":503612556},{"date":"2026-03-06","current":-4.700516,"twenty":-6.238621,"median":-4.26556,"eighty":-2.104054,"marketCap":493394330},{"date":"2026-03-13","current":-4.610121,"twenty":-6.229687,"median":-4.302155,"eighty":-2.104429,"marketCap":483905978},{"date":"2026-03-20","current":-4.026033,"twenty":-6.20894,"median":-4.311653,"eighty":-2.110959,"marketCap":422596623},{"date":"2026-03-27","current":-3.928685,"twenty":-6.202926,"median":-4.267198,"eighty":-2.118489,"marketCap":412378397}],"updateTime":1774788557826},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LXEO\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2602538285","title":"Institutional investors have a lot riding on Lexeo Therapeutics, Inc. (NASDAQ:LXEO) with 56% ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2602538285","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602538285?lang=en_us&edition=fundamental","pubTime":"2026-01-10 22:52","pubTimestamp":1768056773,"startTime":"0","endTime":"0","summary":"Key Insights Institutions' substantial holdings in Lexeo Therapeutics implies that they have significant influence over...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lxeo/lexeo-therapeutics/news/institutional-investors-have-a-lot-riding-on-lexeo-therapeut","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lxeo/lexeo-therapeutics/news/institutional-investors-have-a-lot-riding-on-lexeo-therapeut","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QLD","MNQmain","NQmain","SQQQ","QID","USJW.SI","PSQ","TSYW.SI","USAW.SI","LXEO",".IXIC","NVIW.SI","TQQQ","BK4139"],"gpt_icon":1},{"id":"2601366418","title":"Lexeo Therapeutics Partners with Johnson & Johnson on Targeted Cardiac Gene Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2601366418","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601366418?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:00","pubTimestamp":1767873629,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics Inc., a clinical stage genetic medicine company, has announced a research collaboration with Johnson & Johnson to explore the targeted delivery of AAV gene therapy for cardiovascular diseases. The partnership will combine Lexeo’s expertise in cardiac genetic medicine with Johnson & Johnson’s experience in cardiovascular therapeutics and circulatory technologies, including the use of Impella heart pumps. The agreement aims to accelerate the development of a preclinical cardiac target by investigating novel, localized routes of gene therapy administration, with the goal of improving the efficacy and safety of treatments for genetically mediated cardiovascular diseases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lex","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL2KZxjz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JNJ","LU1261432733.SGD","IE00BVYPNV92.GBP","LU2129689605.HKD","IE00B2B36J28.USD","IE00BLSP4239.USD","LU0070217475.USD","LXEO","SG9999014013.SGD","IE0009355771.USD","LU2602419157.SGD","LU1244550221.USD","LU2471134523.USD","IE00B1BXHZ80.USD","BK4559","LU1244550577.SGD","IE00BDGV0183.EUR","BK4504","LU0889566641.SGD","LU1914381329.SGD","IE00B42XCP33.USD","BK4588","IE00BKPKM429.USD","LU1032466523.USD","NDAQ","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU0345769631.USD","LU2095319765.USD","BK4112","IE00BKVL7J92.USD","LU0124676726.USD","LU2750360641.GBP","LU2210149790.SGD","IE000M9KFDE8.USD","IE00BFXG1179.USD","LU2133065610.SGD","LU1718418525.SGD","LU1585245621.USD","LU1221951129.SGD","LU2112291526.USD","LU1032955483.USD","LU1506573853.SGD","LU2129689514.USD","LU0314104364.USD","LU1935042991.SGD","LU0882574055.USD","IE00B19Z3B42.SGD","LU0114720955.EUR","LU0787776722.HKD"],"gpt_icon":0},{"id":"2601662043","title":"Lexeo Therapeutics Inc - Announces Research Collaboration With Johnson & Johnson","url":"https://stock-news.laohu8.com/highlight/detail?id=2601662043","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601662043?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:00","pubTimestamp":1767873604,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA7WK8G4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2601661143","title":"Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of Aav Gene Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2601661143","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601661143?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:00","pubTimestamp":1767873604,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA7WK8G4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LXEO"],"gpt_icon":0},{"id":"2593703482","title":"Lexeo Therapeutics CEO to Present at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2593703482","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593703482?lang=en_us&edition=fundamental","pubTime":"2025-12-22 20:30","pubTimestamp":1766406607,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 7:30 AM PT in San Francisco, California. The event will be webcast live on the company's website, with a replay available after the presentation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 22, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL9srZdd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4112","LU2095319765.USD","LU2210149790.SGD","LU2210150020.SGD","LXEO","IE00BKPKM429.USD","LU0314104364.USD","SG9999014005.SGD","BK4585","SG9999014013.SGD","BK4588","SG9999014021.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014039.USD","NDAQ","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2592906070","title":"Raymond James Initiates Coverage on Lexeo Therapeutics With Strong Buy Rating, $25 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2592906070","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592906070?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:21","pubTimestamp":1766064109,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics (LXEO) has an average rating of Buy and mean price target of $19.91, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LXEO","RJF"],"gpt_icon":0},{"id":"2592388974","title":"Lexeo Therapeutics Initiated at Strong Buy by Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2592388974","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592388974?lang=en_us&edition=fundamental","pubTime":"2025-12-18 17:55","pubTimestamp":1766051700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXEO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 18, 2025 04:55 ET (09:55 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1363072403.SGD","LXEO","BK4127","RJF","LU0971096721.USD","LU2265009873.SGD","LU1804176565.USD","IE00B3QW5Z07.USD","BK4139","BK4585","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4588"],"gpt_icon":0},{"id":"2590513785","title":"Lexeo Therapeutics Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2590513785","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590513785?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:27","pubTimestamp":1765456020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXEO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 11, 2025 07:27 ET (12:27 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO"],"gpt_icon":0},{"id":"2588145884","title":"Lexeo Therapeutics Hosts Virtual Clinician Event on PKP2-Associated Arrhythmogenic Cardiomyopathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2588145884","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588145884?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:00","pubTimestamp":1764853207,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics Inc. will host a virtual event titled \"A Clinician's Perspective: Holistic Approach to Managing PKP2-Associated Arrhythmogenic Cardiomyopathy\" during the 22nd Global Cardiovascular Clinical Trialists  Forum on Tuesday, December 9th at 3 PM ET. The session will feature Dr. Victoria Parikh of Stanford University, who will discuss clinical management for patients with PKP2-associated arrhythmogenic cardiomyopathy. The event will be accessible to analysts and investors, and a replay will be available on Lexeo's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 04, 2025, and is solely responsible fo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL9v0MCx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU0314104364.USD","IE00BKPKM429.USD","LU2095319765.USD","NDAQ","IE00B3QW5Z07.USD","BK4588","BK4585","LXEO","BK4139","LU2210150020.SGD","BK4112","LU2210149790.SGD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2588731287","title":"Lexeo Therapeutics Initiated at Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2588731287","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588731287?lang=en_us&edition=fundamental","pubTime":"2025-12-01 22:08","pubTimestamp":1764598080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXEO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 01, 2025 09:08 ET (14:08 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO"],"gpt_icon":0},{"id":"2584136718","title":"Lexeo Therapeutics Initiated at Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2584136718","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584136718?lang=en_us&edition=fundamental","pubTime":"2025-11-20 20:07","pubTimestamp":1763640420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXEO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 20, 2025 07:07 ET (12:07 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO"],"gpt_icon":0},{"id":"2584334631","title":"Lexeo Therapeutics initiated with an Overweight at Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2584334631","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584334631?lang=en_us&edition=fundamental","pubTime":"2025-11-20 19:10","pubTimestamp":1763637038,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald initiated coverage of Lexeo Therapeutics (LXEO) with an Overweight rating and $19 price target Published first on TheFly – the ul...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-initiated-with-an-overweight-at-cantor-fitzgerald-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexeo-therapeutics-initiated-with-an-overweight-at-cantor-fitzgerald-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXEO"],"gpt_icon":0},{"id":"2584647279","title":"Optimistic Buy Rating for Lexeo Therapeutics Driven by High-Dose Potential and Superior Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2584647279","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584647279?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:35","pubTimestamp":1763379343,"startTime":"0","endTime":"0","summary":"In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Lexeo Therapeutics, Inc., with a price target of $13.00...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-lexeo-therapeutics-driven-by-high-dose-potential-and-superior-safety-profile-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-lexeo-therapeutics-driven-by-high-dose-potential-and-superior-safety-profile-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXEO","SPN"],"gpt_icon":0},{"id":"2581761980","title":"Lexeo Therapeutics Reports Decreased Losses and Strong Cash Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2581761980","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581761980?lang=en_us&edition=fundamental","pubTime":"2025-11-07 14:54","pubTimestamp":1762498462,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics, Inc. ( ($LXEO) ) has released its Q3 earnings. Here is a breakdown of the information Lexeo Therapeutics, Inc. presented to its...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lexeo-therapeutics-reports-decreased-losses-and-strong-cash-position?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lexeo-therapeutics-reports-decreased-losses-and-strong-cash-position?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LXEO","BK4139"],"gpt_icon":0},{"id":"2581090850","title":"Lexeo Therapeutics unveils gene therapy advances targeting cardiac diseases with no existing treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2581090850","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581090850?lang=en_us&edition=fundamental","pubTime":"2025-11-06 23:49","pubTimestamp":1762444140,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics Inc. has provided an update on its gene therapy programs targeting cardiac diseases with significant unmet medical needs. The company highlighted LX2006, its clinical-stage program for Friedreich Ataxia  cardiomyopathy, the leading cause of death in individuals with FA. Interim clinical data indicate sustained or deepening improvements in both cardiac and neurological measures among most participants. The FDA has expressed openness to a Biologics License Application  submission for accelerated approval, incorporating data from ongoing and planned studies. Lexeo also reported progress on LX2020 for PKP2 arrhythmogenic cardiomyopathy, with safety and efficacy data expected in early January. The company emphasized the use of AAVrh10 vector technology, which has demonstrated increased cardiac targeting and favorable safety profiles in preclinical and clinical programs. You can access the full presentation through the link below.Disclaimer: This news brief was created by ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL9WJjdQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO","BK4139"],"gpt_icon":0},{"id":"2581084860","title":"Lexeo Therapeutics Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2581084860","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581084860?lang=en_us&edition=fundamental","pubTime":"2025-11-06 08:27","pubTimestamp":1762388820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LXEO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 05, 2025 19:27 ET (00:27 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO"],"gpt_icon":0},{"id":"2581722573","title":"Lexeo Therapeutics Q3 EPS $(0.33) Beats $(0.54) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581722573","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581722573?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:37","pubTimestamp":1762346275,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.54) by 38.78 percent. This is a 62.92 percent increase over losses of $(0.89) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48649935/lexeo-therapeutics-q3-eps-0-33-beats-0-54-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LXEO"],"gpt_icon":0},{"id":"2581722652","title":"Lexeo Therapeutics reports interim LX2006 trial data showing improvements in cardiac and neurologic measures","url":"https://stock-news.laohu8.com/highlight/detail?id=2581722652","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581722652?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:37","pubTimestamp":1762346232,"startTime":"0","endTime":"0","summary":"Lexeo Therapeutics Inc. reported a cash position of $122.8 million as of September 30, 2025, excluding $153.8 million in proceeds from an October 2025 public offering and concurrent PIPE. The company closed an oversubscribed $154 million equity financing in October 2025, which, combined with existing cash and investments, is expected to fund operations into 2028. Lexeo also announced business developments, including the completion of enrollment in the LX2020 HEROIC-PKP2 Phase I/II trial and FDA approval of a comparability report for LX2006 manufacturing processes. Interim clinical data for LX2006 showed a mean improvement in left ventricular mass index and stabilization or improvement in secondary cardiac biomarkers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL5tsSNr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BKPKM429.USD","LU0314104364.USD","LU2095319765.USD","IE00B3QW5Z07.USD","LXEO","NDAQ","LU2210150020.SGD","BK4588","BK4112","LU2210149790.SGD","BK4585","BK4139","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2581722920","title":"Lexeo Therapeutics Inc - EPS $-0.33 for Q3","url":"https://stock-news.laohu8.com/highlight/detail?id=2581722920","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581722920?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:36","pubTimestamp":1762346215,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nTUA6DVFRZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LXEO","BK4139"],"gpt_icon":0},{"id":"2581722614","title":"Press Release: Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2581722614","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581722614?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:36","pubTimestamp":1762346160,"startTime":"0","endTime":"0","summary":"FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier co-primary endpoint assessment, to support a Biologics License Application. FDA approved comparability report between LX2006 HEK and Sf9 manufacturing processes in November 2025, endorsing use of Sf9 final commercial manufacturing process to begin dosing patients in upcoming pivotal study. LX2006 interim clinical data show clinically meaningful improvements across cardiac and neurologic measures of Friedreich ataxia, including left ventricular mass index and the modified Friedreich Ataxia Rating Scale. Completed enrollment of LX2020 HEROIC-PKP2 Phase I/II trial with ten participants dosed; interim data from low-dose cohort reported and additional clinical data from high-dose cohorts on track for January 2026. $154 million equity financing to support LX2006 registrational activities and further development of cardiac pipeline; in addition to Q3-25 end cash, cash equivalents an","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VT","BK4539","FA","BK4110","BK4588","BK4535","BK4130","LFT","LXEO","BK4585","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":70,"code":"91000000","status":"200"}]}}